

17u



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pre Patent Application of

BORMAN et al.

Atty. Ref.: 620-410

Serial No. 10/564,010 ✓

Group: unknown

Filed: January 10, 2006

Examiner: Unknown

For: 5-HT2B RECEPTOR ANTAGONISTS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 10, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:


- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: 

B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-410

10/564,010

APPLICANT

BORMAN et al.

FILING DATE

GROUP

January 10, 2006

unknown

U.S. PATENT DOCUMENTS*EXAMINER
INITIALPATENT & TRADEMARK OFFICE
DOCUMENT NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE**FOREIGN PATENT DOCUMENTS**

TRANSLATION

DOCUMENT

DATE

COUNTRY

CLASS

SUBCLASS

YES

NO

DE 198 51 421 05/2000 Germany

EP 0 710 654 05/1996 Europe

FR 1 513 739 02/1968 France

GB 681 712 10/1952 Great Britain

GB 2 230 527 10/1990 Great Britain

RO 63449 05/1978 Romania

WO 96/20932 07/1996 WIPO

WO 94/09017 04/1994 WIPO

WO 2004/009017 01/2004 WIPO

WO 03/068226 08/2003 WIPO

WO 96/24351 08/1996 WIPO

WO 01/08668 02/2001 WIPO

WO 03/006443 01/2003 WIPO

WO 03/072569 09/2003 WIPO

WO 02/083628 10/2002 WIPO

WO 01/28561 04/2001 WIPO

WO 01/19801 03/2001 WIPO

WO 98/16515 04/1998 WIPO

WO 95/03286 02/1995 WIPO

WO 01/14372 03/2001 WIPO

WO 00/23444 04/2000 WIPO

WO 95/24200 09/1995 WIPO

WO 02/092576 11/2002 WIPO

WO 97/44326 11/1997 WIPO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Hoyer et al, Pharmacological Review, 1994, Vol. 46, No. 2, pp 157-203

Kato et al, Chem. Pharm. Bull. 1977, Vol. 25, No. 2, pp 215-220

Launay et al, Nature Medicine, 2002, Vol. 8, No. 10, pp 1129-1135

van Leusen et al, J. Org. Chem. 1981, Vol. 46, pp 2069-2072

Marchetti, J. Med. Chem. 1968, Vol. 11, pp 1092-1093

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.

620-410

APPLICANT

BORMAN et al.

FILING DATE

January 10, 2006

SERIAL NO.

10/564,010

GROUP

unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Martin et al, Neuropharmacology, 1994, Vol. 33, No. 3/4 pp 261-273
	Molina et al, Synthesis, 1993, Vol. 1, pp 54-56
	Nath et al, Indian J. Chem., 1980, Vol. 19B, pp 526-529
	Newton et al, Global Outsourcing Review, 2003, Vol. 5, No. 2, pp 1-5
	Nishiwaki, Chem. Pharm. Bull., 1962, , Vol. 10, pp 1029-1032
	O'Brien et al, J. Org. Chem., 1962, Vol. 27, pp 1104-1107
	Pattanayak et al, Indian J. Chem., 1978, Vol. 16B, pp 1030-1032
	Pattanayak et al, J. Indian Chem. Soc., 1978, Vol. LV, pp 264-267
	Phillips et al, J. Am. Chem. Soc., 1952, Vol. 74, pp 3922-3924
	Rahman et al, Bioorganic & Medicinal Chemistry Letters, 2003, Vol. 13, pp 1119-1123
	Reiter et al, J. Heterocyclic Chem., 1986, Vol. 23, pp 401-408
	Tanaka et al, Chem. Abs. 1967, 66:94930
	Tidwell et al, Journal of Medicinal Chemistry, 1978, Vol. 21, No. 7, pp 613-623
	Vullo et al, Bioorganic & Medicinal Chemistry Letters, 2003, Vol. 13, pp 1005-1009
	Watanabe et al, Chem. Pharm. Bull., 1987, Vol. 35, No. 4, pp 1452-1459
	Ainley et al, J. Chem. Soc., 1953, pp 59-70
	Ali et al, Bioorganic & Medicinal Chemistry Letters, 2001, Vol. 11, pp 2185-2188
	Banks, J. Am. Chem. Soc., 1944, Vol. 66, No. 7, 1131
	Bansal, Chem. Abs. 2000:100697
	Bansal et al, Oriental Journal of Chemistry, 1999, Vol. 15, No. 3, pp 489-494
	Bansal et al, Indian Journal of Chemistry, 2000, Vol. 39B, pp 357-362
	Bansal et al, Eur. J. Med. Chem., 2001, Vol. 36, pp 81-92
	Berge et al, Journal of Pharmaceutical Sciences, 1977, Vol. 66, No. 1, pp 1-19
	Berger et al, JID, 1996, Vol. 174, pp 659-662
	Blank et al, Journal of Medicinal Chemistry, 1972, Vol. 15, No. 6, pp 694-696
	Cavalleri et al, IL Farmaco - Ed. Sc., 1976, Vol. 31, pp 393-402
	Cavalleri et al, Arzneim.-Forsch./Drug Res., 1977, 27 (II), No. 10, pp 1889-1895
	Cockerill et al, Synthesis, 1976, pp 591-593
	Cooper et al, J. Med. Chem., 1990, Vol. 33, pp 1246-1252
	Crank et al, Journal of Medicinal Chemistry, 1971, Vol. 14, No. 11, pp 1075-1077

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-410

10/564,010

APPLICANT

BORMAN et al.

FILING DATE

GROUP

January 10, 2006

unknown

(Use several sheets if necessary)

MAY 10 2006

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		2,585,910	02/1952	Barton et al			
		2,643,253	06/1953	Swinden et al			
		3,464,987	09/1969	Ursprung et al			
		5,679,678	10/1997	Binder et al			
		5,840,893	11/1998	Bukrinsky et al			
		5,952,331	09/1999	Berger et al			
		5,958,934	09/1999	Berger et al			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

[illegible]

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)